Our findings were parallel to the findings of previous studies where MALAT1 promoted drug resistance in cancer cells via modulating STAT3 activation in lung cancer and enhanced FUT4 fucosylation by sponging miR-26a/26b involving PI3K/AKT pathway (Xu et al., 2020). Here, STAT3 is linked to lung cancer.